Clinical Trial

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

Study acronym: CT1190B
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 23, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.
Trial Details
NCT Number NCT07032324
Lead Sponsor Qian Wenbin
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions B-Cell Non-Hodgkin Lymphoma
Enrollment 27 participants
Start Date 2025-07-08
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-23